Albireo Pharma, Inc.
ALBO · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 19.8% | 20.1% | -79% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 93.8% | 90.5% | 96.6% | 97.2% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -357.5% | -452.3% | -577.3% | 25.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -390.7% | -520.3% | -663.2% | -33.7% |
| EPS Diluted | -1.95 | -2.18 | -2.34 | -0.57 |
| % Growth | 10.6% | 6.8% | -310.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |